887 related articles for article (PubMed ID: 21343549)
1. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
[TBL] [Abstract][Full Text] [Related]
5. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
Metzeler KH; Becker H; Maharry K; Radmacher MD; Kohlschmidt J; Mrózek K; Nicolet D; Whitman SP; Wu YZ; Schwind S; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
Blood; 2011 Dec; 118(26):6920-9. PubMed ID: 22031865
[TBL] [Abstract][Full Text] [Related]
6. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
8. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
9. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
11. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
Pastore F; Dufour A; Benthaus T; Metzeler KH; Maharry KS; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Kakadia PM; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Sauerland MC; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Bohlander SK; Marcucci G; Spiekermann K; Bloomfield CD; Hoster E
J Clin Oncol; 2014 May; 32(15):1586-94. PubMed ID: 24711548
[TBL] [Abstract][Full Text] [Related]
12. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
13. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
14. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
16. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
19. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
